Teva Announces Updated Indication and Vial Presentation for Granix (tbo-filgrastim) Injection in United States
JERUSALEM--(BUSINESS WIRE)--Aug. 6, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved Granix (tbo-filgrastim) Injection for a new vial presentation and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 6, 2018 Category: Drugs & Pharmacology Source Type: news
Nivestym (Filgrastim-aafi Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 6, 2018 Category: Drugs & Pharmacology Source Type: news
Second Filgrastim Biosimilar Gets Thumbs Up From the FDA Second Filgrastim Biosimilar Gets Thumbs Up From the FDA
The FDA has granted approval to Nivestym, which has several clinical uses.FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 20, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
FDA Approves Nivestym (filgrastim-aafi), a Biosimilar to Neupogen
July 20, 2018 - Pfizer Inc. (NYSE:PFE) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nivestym (filgrastim-aafi), a biosimilar to Neupogen1 (filgrastim), for all eligible indications of the reference... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 20, 2018 Category: Drugs & Pharmacology Source Type: news
Neupogen (Filgrastim Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 11, 2018 Category: Drugs & Pharmacology Source Type: news
Kirin-Amgen Joint Venture To Become Wholly-Owned Subsidiary Of Amgen
$780 Million Payment to be Funded From Joint Venture's Existing Cash Holdings
Kyowa Hakko Kirin to Continue as Licensee in Asia
THOUSAND OAKS, Calif., Oct. 30, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that Amgen and Kirin Holdings (Kirin) have agreed that Kirin-Amgen, a joint venture between the two companies, will redeem Kirin's shares in the joint venture and, as a result, Kirin-Amgen will become a wholly-owned subsidiary of Amgen.
Kirin-Amgen was established in 1984 as a 50-50 joint venture between Amgen and Kirin to fund the global development of EPOGEN® (epoetin alfa). Over time, the scope ...
Source: Amgen News Release - October 31, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Are Biobetters Better?
Biosimilars and biobetters are both variants of a biologic drug, however, while biosimilars are close copies of the originator, biobetters have been improved, for example, in terms of efficacy, safety, tolerability or dosing regimen.Regulators consider biobetters as new products and so afford them the same patent protection as any originator, however, this means they require the same clinical and non-clinical data packages. Conversely, a reduced clinical data package is an attractive element for the development of biosimilars.Given the cost of development and the time pressure to bring a biobetter to market before biosimil...
Source: EyeForPharma - July 3, 2017 Category: Pharmaceuticals Authors: James Wright Source Type: news
Zarxio (Filgrastim-sndz Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 2, 2017 Category: Drugs & Pharmacology Source Type: news
Granix (Tbo-filgrastim Injection, for Subcutaneous Use) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 16, 2017 Category: Drugs & Pharmacology Source Type: news
Neupogen® (Filgrastim): General Information for Clinicians
Centers for Disease Control and Prevention, National Center for Environmental Health. 12/10/2015This resource provides information about Neupogen (Filgrastim), which was approved in March 2015 by the U.S. Food and Drug Administration (FDA) to treat people who have received high doses of radiation. Neupogen is a drug that has been used successfully for cancer patients to produce more white blood cells. The fact sheet discusses who can take Neupogen, how it is given, and its side effects. (Text) (Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health)
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - April 28, 2016 Category: Global & Universal Authors: The U.S. National Library of Medicine Source Type: news
Zarxio (Filgrastim-sndz Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 16, 2016 Category: Drugs & Pharmacology Source Type: news
What is the Difference Between Neulasta and...
Neutropenia during chemotherapy is treated with Neulasta or Neupogen. What's the difference, why is each chosen and what are the costs? (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - March 16, 2016 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news
NLM’s Radiation Emergency Medical Management (REMM) Site Redesigned
The National Library of Medicine’s Radiation Emergency Medical Management (REMM) site has been redesigned. REMM now includes a more modern banner, a refreshed color palette and font style, and a new navigation system.
There are six content groups and an easy-to-use navigational menu on the home page with sections for:
Interactive Clinical Tools,
Diagnosis and Treatment,
Reference and Data,
Overview of REMM, and
Links to downloading the REMM app for various mobile devices
Significant content updates have been added including:
New references and on most of the Emergencies Incidents pages
New references in the Key...
Source: Dragonfly - October 9, 2015 Category: Databases & Libraries Authors: Emily Glenn Tags: Emergency Preparedness News from NLM Technology Source Type: news
